Learn Data For Researchers Find trials matched to me

Learn Data For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Take one of two hormone medication combinations for prostate cancer | stella

Back to Recurrent Prostate Carcinoma trials

Recruiting

Comparing two hormone treatments for advanced prostate cancer

Plain-English translation of NCT06650579 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a newer hormone medication called works better than a standard older medication called when combined with for treating advanced prostate cancer. The main focus is on heart safety—doctors want to know which combination is gentler on your heart over two years of treatment. You'll also receive radiation therapy as part of your standard cancer care.

Hormone-blocking medications can sometimes cause heart problems in prostate cancer patients. This study wants to find out if the newer treatment option causes fewer heart issues than the traditional approach, so doctors can offer their patients the safest option.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with non-metastatic (not spread beyond the pelvis) prostate cancer or recurrent prostate cancer
you are planning to receive radiation therapy to the pelvis as your main cancer treatment
you have not received hormone therapy for prostate cancer before
you are willing to take hormone-blocking medications and additional drugs for up to 24 months

You likely don't qualify if…

you have cancer that has spread to distant parts of your body
you have received any prior chemotherapy, radiation, or immunotherapy
you have a history of heart surgery, stents, pacemakers, or defibrillators
you have received hormone therapy for prostate cancer in the past

What participation looks like

You will be randomly assigned to receive one of two medication combinations, both taken alongside your radiation therapy. One group takes injections every 3 to 6 months plus daily pills; the other takes a daily pill instead. You'll visit the clinic for heart imaging scans and blood tests before treatment starts and again at 12 months, then have follow-up blood work at 30 and 60 days after your treatment ends. The entire medication phase lasts up to 24 months.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(4 sites)

United States

Emory Proton Therapy Center, Atlanta, Georgia

Winship at Emory Midtown, Atlanta, Georgia

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Emory Saint Joseph's Hospital, Atlanta, Georgia

Key details

Phase

Large-scale testing

Sponsor

Emory University

Collaborators

Pfizer, Sumitomo Pharma America, Inc.

Enrollment target

~72 participants

Started

January 2025

Primary completion

July 2029

Age range

18 Years and older

Sex

Male only

Last updated on clinicaltrials.gov in February 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Bill Zheng, BS

Emory University Hospital/Winship Cancer Institute

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov